Table 1. Characteristics of Patients With Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibition in the Pooled Cohort of Patients From the Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and Stand Up To Cancer/Mark Foundation Data Sets, According to TMB Status.
| Clinical characteristic | Patients, No. (%) | |
|---|---|---|
| Low TMB (n = 1391) | High TMB (n = 161) | |
| Age, median (range), y | 67 (22-92) | 65 (44-83) |
| Sex | ||
| Male | 639 (45.9) | 83 (51.6) |
| Female | 752 (54.1) | 78 (48.4) |
| Smoking status | ||
| Current or former | 1165 (83.8) | 157 (97.5) |
| Never | 226 (16.2) | 4 (2.5) |
| Histologic profile | ||
| Nonsquamous | 1198 (86.1) | 149 (92.5) |
| Squamous | 193 (13.9) | 12 (7.5) |
| Oncogenic driver mutation | ||
| KRAS | 482 (34.7) | 38 (23.6) |
| EGFR | 138 (9.9) | 5 (3.1) |
| Other | 120 (8.6) | 15 (9.3) |
| None identified | 651 (46.8) | 103 (64.0) |
| Eastern Cooperative Oncology Group performance status | ||
| 0-1 | 1058 (85.5) | 127 (89.4) |
| ≥2 | 179 (14.5) | 15 (10.6) |
| Not assessed | 154 (NA) | 19 (NA) |
| Line of therapy | ||
| First | 473 (34.0) | 58 (36.0) |
| Second or higher | 918 (66.0) | 103 (64.0) |
| PD-L1 expression | ||
| <1% | 251 (27.4) | 30 (28.3) |
| 1%-49% | 257 (28.1) | 30 (28.3) |
| ≥50% | 407 (44.5) | 46 (43.4) |
| Not assessed | 476 (NA) | 55 (NA) |
Abbreviations: NA, not applicable; PD-1, programmed cell death–1; PD-L1, programmed death ligand 1; TMB, tumor mutation burden.